Every intervention Outliyr has scored for nerve regeneration, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for nerve regeneration; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
25 of 72 evaluated interventions score 3.0+ out of 10 for nerve regeneration · 4 comparisons
BPC-157 nerve regeneration earns 7.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits nerve regeneration when the target is tissue repair, vascular recruitment, or inflammation control, but the case still…
Read the BPC-157 report →Nerve-regeneration scores 6.8/10 because Hamblin 2018 supports neurorepair mechanisms in photobiomodulation, while peripheral nerve trials remain condition-specific. The mechanism is plausible through mitochondrial support, Schwann-cell signaling, blood flow, and inflammation control. The…
Read the Red Light Therapy report →Lion's Mane nerve regeneration earns 6.5/10 because Willis 2025 anchors the most relevant signal. Lion's Mane fits nerve regeneration when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or…
Read the Lion’s Mane report →The 6.2/10 nerve regeneration score reflects evidence plus practical constraints. Peripheral nerve pilot data and carpal tunnel adjunct use justify a moderate exploratory score, but the evidence is not as mature as…
Read the PEMF (Pulsed Electromagnetic Field Therapy) report →TB-500 (Thymosin Beta-4 Fragment) fits nerve regeneration at 6.0/10 when the baseline problem is real. Nerve-regeneration support comes from stroke and brain-injury remodeling models rather than human peripheral-nerve trials. Morris 2010 supports…
Read the TB-500 (Thymosin Beta-4 Fragment) report →For readers tracking nerve regeneration, GHK-Cu deserves 6.0/10 because Kang et al. 2009 gives the strongest anchor. The v0 score remains because GHK-related nerve outgrowth and neuronal-protection signals exist, but mostly outside…
Read the GHK-Cu report →The evidence base for Whole-Body Vibration supporting nerve-regeneration scores 5.5/10, with only small neuropathy trials reporting symptom relief but no confirmed regrowth Wang et al. 2024. Whole-Body Vibration may improve local blood…
Read the Whole-Body Vibration report →Nerve regeneration is ARA-290's strongest case and the reason it scores at the top of this group. In the Phase 2b dose-ranging trial, 4 mg per day raised corneal nerve fiber area…
Read the ARA-290 (Cibinetide) report →Support is plausible through injury repair, CRPS, radiation injury, and neurorehab studies. Kiralp 2004 reports CRPS pain and function gains after a small RCT of hyperbaric oxygen. Direct peripheral nerve regeneration outcomes…
Read the Hyperbaric Oxygen Therapy report →Aerobic exercise may support nerve health indirectly through glucose control, blood flow, and neurotrophic signaling. Direct human evidence for nerve regeneration from Zone 2 specifically is limited, so this remains an exploratory…
Read the Zone 2 Cardio report →No direct nerve-regeneration evidence was verified for EAA supplementation. The score stays below neutral.
Read the Essential Amino Acids report →No direct human nerve-regeneration evidence for glycine supplementation.
Read the Glycine report →Nerve regeneration data are entirely preclinical for native Tβ4, but the rodent signal is consistent across stroke and traumatic brain injury models. In rat embolic stroke, Tβ4 improved neurological functional outcome and…
Read the Thymosin Beta-4 (Tβ4) report →Russian optic-nerve use and preclinical neural protection make nerve repair a plausible research direction, but human nerve-regeneration trials remain limited.
Read the Semax report →No direct nerve-regeneration evidence. Keep below neutral until peripheral nerve or neuropathy trials exist.
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →GLP-1 neuroprotection research does not translate into established peripheral nerve regeneration evidence for semaglutide.
Read the Semaglutide report →INSUFFICIENT_EVIDENCE for nerve regeneration in healthy users or clinical neuropathy contexts.
Read the Rapamycin report →Metformin can complicate neuropathy through B12 depletion. Ballal 2025 supports ongoing concern around long-term metformin, B12 deficiency, and peripheral neuropathy monitoring.
Read the Metformin report →NAD+ supports neuronal health and NADPARK suggests neuroprotective potential, but direct human nerve-regeneration evidence for NR remains limited.
Read the NR (Nicotinamide Riboside) report →Tirzepatide may improve diabetes risk factors that contribute to neuropathy progression. There is no direct nerve regeneration trial. Existing benefits are preventive or metabolic, not regenerative. Score low and frame as metabolic…
Read the Tirzepatide report →One animal repair signal exists: Weiss 2021 studied stem cells, G-CSF, and/or dihexa in a rat sciatic nerve damage-repair model. This is not standalone human nerve-regeneration evidence.
Read the Dihexa report →Animal neurogenesis data do not equal nerve-regeneration evidence. No peripheral neuropathy, nerve crush, diabetic neuropathy, or radiculopathy human RCT supports clinical use.
Read the Thymosin Alpha-1 report →Preclinical nerve-repair data exist, but human clinical evidence is thin.
Read the Omega-3 report →TRT has limited human evidence for nerve regeneration. If neuropathy or nerve injury exists, address glucose, B vitamins, compression, inflammation, rehabilitation, and specialist care first.
Read the TRT (Testosterone Replacement Therapy) report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Cerebrolysin scores 6.3 and P-21 scores 5.0, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.9 and dihexa 4.4, and the gap is entirely safety: dihexa potentiates the…
Semax scores 7.1 and cerebrolysin 6.3. Semax wins cognition, neuroplasticity and nerve regeneration, costs an ESTIMATED $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.1 against dihexa's 4.4, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
BPC-157, at 7.5 out of 10 for nerve regeneration. BPC-157 nerve regeneration earns 7.5/10 because Vasireddi 2025 anchors the most relevant signal.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 4.5 out of 10 for nerve regeneration.
Dihexa scores 3.5 out of 10 for nerve regeneration but only 4.4 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
25 of the 72 interventions evaluated for nerve regeneration score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
